Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2006

Open Access 01-12-2006 | Review

Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy

Authors: Crispin R Dass, Peter FM Choong

Published in: Cancer Cell International | Issue 1/2006

Login to get access

Abstract

Cationic (positively charged) liposomes have been tested in various gene therapy clinical trials for neoplastic and other diseases. They have demonstrated selectivity for tumour vascular endothelial cells raising hopes for both antiangiogenic and antivascular therapies. They are also capable of being selectively delivered to the lungs and liver when administered intravenously. These vesicles are being targeted to the tumour in various parts of the body by using advanced liposomal systems such as ligand-receptor and antibody-antigen combinations. At present, the transferrin receptor is commonly used for cancer-targeted drug delivery systems including cationic liposomes. This review looks at the growing utility of these vesicles for delivery of small molecule anticancer drugs.
Appendix
Available only for authorised users
Literature
1.
Dass CR, Burton MA: A model for evaluating selective delivery of plasmid DNA to tumours via the vasculature. Cancer Biother Radiopharm. 2002, 17: 501-5. 10.1089/108497802760804727.CrossRefPubMed
2.
Park JW, Benz CC, Martin FJ: Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol. 2004, 31 (6 Suppl 13): 196-205. 10.1053/j.seminoncol.2004.08.009.CrossRefPubMed
3.
Sapra P, Tyagi P, Allen TM: Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005, 2 (4): 369-81. 10.2174/156720105774370159.CrossRefPubMed
4.
Felgner PL, Gadek TR, Holm M: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA. 1987, 84: 7413-7. 10.1073/pnas.84.21.7413.PubMedCentralCrossRefPubMed
5.
Dass CR: Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy. Int J Pharmaceut. 2002, 241: 1-25. 10.1016/S0378-5173(02)00194-1.CrossRef
6.
Hafez IM, Maurer N, Cullis PR: On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001, 8: 1188-96. 10.1038/sj.gt.3301506.CrossRefPubMed
7.
Zuidam NJ, Barenholz Y: Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta. 1998, 1368: 115-28. 10.1016/S0005-2736(97)00187-9.CrossRefPubMed
8.
Dass CR: Vehicles for oligonucleotide delivery: Therapeutic applicability against tumors. J Pharm Pharmacol. 2002, 54: 3-27. 10.1211/0022357021771887.CrossRefPubMed
9.
Lasic DD, Pearlman R: Liposomes and lipidic particles in gene therapy. Edited by: Rosoff M. 1996, Vesicles. Brooklyn (NY): Marcel Dekker, 477-89.
10.
Farhood H, Serbina N, Huang L: The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta. 1995, 1235: 289-95. 10.1016/0005-2736(95)80016-9.CrossRefPubMed
11.
Dass CR, Walker TL, Kalle WHJ, Burton MA: A microsphere-lipoplex (microplex) vector for targeted gene therapy of cancer. I. Construction and in vitro evaluation. Drug Delivery. 1999, 6: 259-270. 10.1080/107175499266850.CrossRef
12.
Wheeler CJ, Felgner PL, Tsai YJ: A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sc USA. 1996, 93: 11454-59. 10.1073/pnas.93.21.11454.CrossRef
13.
Dass CR: Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol. 2002, 128 (4): 177-81. 10.1007/s00432-001-0318-x.CrossRefPubMed
14.
Ren T, Song YK, Zhang G: Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther. 2000, 7: 764-68. 10.1038/sj/gt/3301153.CrossRefPubMed
15.
Leventis R, Silvius JR: Interactions of mammalian cells with lipid dispersions containing metabolizable cationic amphiphiles. Biochim Biophys Acta. 1990, 1023: 124-32. 10.1016/0005-2736(90)90017-I.CrossRefPubMed
16.
Dass CR: Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med. 2004, 82 (9): 579-91. 10.1007/s00109-004-0558-8.CrossRefPubMed
17.
Dass CR: Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm. 267 (1–2): 1-12. 2003 Nov 28
18.
Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002, 62: 6831-6836.PubMed
19.
Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodle MC, Papahadjopoulos D: Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 1998, 273: 15621-7. 10.1074/jbc.273.25.15621.CrossRefPubMed
20.
Vincent S, DePace D, Finkelstein S: Distribution of anionic sites on the capillary endothelium in an experimental brain tumour model. Microcirc Endothelium Lymphatics. 1988, 4: 45-67.PubMed
21.
Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs R: Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem. 1998, 273: 26164-26170. 10.1074/jbc.273.40.26164.CrossRefPubMed
22.
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL: Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000, 97: 14608-14613. 10.1073/pnas.97.26.14608.PubMedCentralCrossRefPubMed
23.
Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB: Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther. 1999, 6 (3): 403-11. 10.1038/sj.gt.3300837.CrossRefPubMed
24.
Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998, 101: 1401-1413.PubMedCentralCrossRefPubMed
25.
Milici AJ, L'Hernault N, Palade GE: Surface densities of diaphragmed fenestrae and transendothelial channels in different murine capillary beds. Circ Res. 1985, 56: 709-717.CrossRefPubMed
26.
27.
Kerbel RS, Klement G, Pritchard KI, Kamen B: Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol. 2002, 13: 12-5. 10.1093/annonc/mdf093.CrossRefPubMed
28.
Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P: Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol. 2003, 120: 476-482. 10.1046/j.1523-1747.2003.12057.x.CrossRefPubMed
29.
Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M: Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 110 (1): 117-24. 10.1002/ijc.20083. 2004 May 20
30.
Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res. 2003, 9 (6): 2335-41.PubMed
31.
Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M: Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer. 105 (4): 561-7. 10.1002/ijc.11108. 2003 Jul 1
32.
Xu L, Pirollo KF, Chang EH: Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther. 1997, 8 (4): 467-75. 1997 Mar 1, Hum Gene Ther, 8, 467–475CrossRefPubMed
33.
Xu L, Pirollo KF, Tang WH, Rait A, Chang EH: Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 10 (18): 2941-52. 10.1089/10430349950016357. 1999 Dec 10
34.
Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF, Rait A, Chang EH: Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med. 2001, 7 (10): 723-34.PubMedCentralPubMed
35.
Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH: Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 2002, 1 (5): 337-46.PubMed
36.
Yu W, Pirollo KF, Rait A, Yu B, Xiang LM, Huang WQ, Zhou Q, Ertem G, Chang EH: A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther. 2004, 11 (19): 1434-40. 10.1038/sj.gt.3302304.CrossRefPubMed
37.
Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH: Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther. 2006, 17 (1): 117-24. 10.1089/hum.2006.17.117.CrossRefPubMed
38.
Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL, Collins D: Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996, 1281: 139-149. 10.1016/0005-2736(95)00268-5.CrossRefPubMed
39.
Dass CR: Targeted gene therapy for cancer. PhD thesis. 1999, Charles Sturt University, New South Wales, Australia
40.
Whitmore M, Li S, Huang L: LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 1999, 6 (11): 1867-75. 10.1038/sj.gt.3301026.CrossRefPubMed
41.
Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I, Wilson DR, Wu Z, Branch CD, Minna JD, Roth JA: Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther. 2001, 3 (3): 337-50. 10.1006/mthe.2001.0266.CrossRefPubMed
42.
Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 62 (15): 4282-8. 2002 Aug 1
43.
Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nogawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T, Irimura T: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res. 10 (22): 7721-6. 10.1158/1078-0432.CCR-04-1049. 2004 Nov 15
44.
Dass CR, Burton MA: Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in vivo. J Pharm Pharmacol. 2003, 55: 19-25.CrossRefPubMed
45.
Burton MA, Gray BN, Kelleher DK, Klemp PF: Selective internal radiation therapy: validation of intraoperative dosimetry. Radiology. 1990, 175 (1): 253-5.CrossRefPubMed
46.
Burton MA, Gray BN, Klemp PF, Kelleher DK, Hardy N: Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol. 1989, 25 (10): 1487-91. 10.1016/0277-5379(89)90109-0.CrossRefPubMed
47.
Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF: rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res. 62 (11): 3077-83. 2002 Jun 1
48.
Stuart DD, Allen TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim Biophys Acta. 2000, 1463: 219-229. 10.1016/S0005-2736(99)00209-6.CrossRefPubMed
49.
Bartsch M, Weeke-Klimp AH, Hoenselaar EP, Stuart MC, Meijer DK, Scherphof GL, Kamps JA: Stabilized lipid coated lipoplexes for the delivery of antisense oligonucleotides to liver endothelial cells in vitro and in vivo. J Drug Target. 2004, 12 (9–10): 613-21. 10.1080/10611860400013519.CrossRefPubMed
50.
Dass CR, Walker TL, Kalle WHJ: A microsphere-lipoplex (microplex) vector for targeted gene therapy of cancer. II. In vivo biodistribution study in a solid tumor model. Drug Deliv. 2000, 7: 15-20. 10.1080/107175400266740.CrossRefPubMed
51.
Steel JC, Cavanagh HM, Burton MA, Dingwall DJ, Kalle WH: Modification of liposomal concentration in liposome/adenoviral complexes allows significant protection of adenoviral vectors from neutralising antibody, in vitro. J Virol Methods. 2005, 126 (1–2): 31-6. 10.1016/j.jviromet.2005.01.017.CrossRefPubMed
52.
Saravolac EG, Ludkovski O, Skirrow R, Ossanlou M, Zhang YP, Giesbrecht C, Thompson J, Thomas S, Stark H, Cullis PR, Scherrer P: Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity. J Drug Target. 2000, 7 (6): 423-37.CrossRefPubMed
53.
Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I: Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta. 1669 (2): 155-63. 2005 May 20
54.
Dass CR, Walker TL, Decruz EE, Burton MA: Enhanced anticancer therapy mediated by specialized liposomes. J Pharm Pharmacol. 1997, 49 (10): 972-5.CrossRefPubMed
Metadata
Title
Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy
Authors
Crispin R Dass
Peter FM Choong
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2006
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-6-17

Other articles of this Issue 1/2006

Cancer Cell International 1/2006 Go to the issue

Primary research

Multicellular Tumour Spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring

Primary research

Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells

Hypothesis

Stem cells, senescence, neosis and self-renewal in cancer

Primary research

Expression of EpCAM in uveal melanoma

Primary research

Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma

Primary research

Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits